Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)
Study sponsor: Akebia Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-11-26Actual
Enrollment · participants319Actual
Source updated2025-05-22Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.